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3NTRODUCTION
This commentary, sponsored by the National
arrow Donor Program (NMDP), provides guide-
ines for unrelated hematopoietic cell donor selection
n the format of frequently asked questions. The pur-
ose of this document is to review the current relevant
ata and provide guidelines that we believe represent
ptimal donor-recipient matching.
UESTION AND ANSWER
hat Is the Purpose of the NMDP Donor-Recipient
atching Criteria?
Since its inception in 1987, the NMDP has required
valuation of donor-recipient matching at HLA-A, -B,
nd -DR. Theminimum acceptablematch was originally
eﬁned by serologic splits at these 6 loci and required at
east 5 matches, ie, a 5 of 6 match. Although the required
evel of resolution has evolved over the years and
LA-DR is now evaluated at the DRB1 allele level, the
asic minimum requirement for a 5 of 6 match has not
hanged. This is because there are abundant data to
how that HLAmatching at this minimum level can lead
o successful transplantation outcomes. However, it is
lso clear that transplantation outcomes can be improved
y matching strategies that increase the degree of HLA
ompatibility above the minimum (eg, matching for
LA-C).
hat Literature Discusses the Effect of HLA on
arrow Transplantation Outcome?
There are many studies that evaluate the role of
LA matching in outcome. We have chosen to focus h
10n large, contemporary studies from 3 groups that
ave evaluated most of the HLA loci by using DNA
esting to resolve alleles.
. Japanese Marrow Donor Program [1]: the study by
Morishima et al. is a follow-up to an earlier study
by Sasazuki et al. [2] in 1998.
. Fred Hutchinson Cancer Research Center: this in-
cludes a series of studies by Petersdorf et al. [3-5].
. NMDP: an abstract on this study by Flomenberg et
al. was presented in 2001 [6], and a manuscript is in
preparation.
f the Several Outcome Measures, Which Is the
ost Important to Consider?
This commentary is focused primarily on the ef-
ect of HLA matching on survival. The effect of spe-
iﬁc HLA mismatches on speciﬁc outcomes such as
raft failure and the incidence of acute and chronic
raft-versus-host disease (GVHD) should not be the
rimary determinant of donor selection but, instead,
hould be used to assign a speciﬁc risk-adapted treat-
ent strategy to the recipient.
hat Do the 3 Studies Suggest Regarding the
ssociation between HLA Matching and Patient
urvival?
Associations between HLA disparity and survival
iffer in the studies as shown in Table 1.
hy Do Studies Give Different Results?
Potential differences in the 3 studies are numerous
nd are summarized in Table 2. Sample sizes limitedReceived August 21, 2003; accepted August 25,
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ow the mismatches were classiﬁed across the multi-
ple loci, and different studies collapsed the loci differ-
ently. Morishima et al. [1] collapsed mismatches on A
and B together and on DR and DQ together to get a
larger sample size for detecting differences among
groups. Petersdorf et al. [3] collapsed mismatches on
the basis of class I versus class II loci. Flomenberg et
al. [6] looked at each locus separately. Neither
Flomenberg et al. nor Petersdorf et al. [3] detected
signiﬁcant locus-speciﬁc differences in survival,
whereas Morishima et al. identiﬁed the combined A/B
group as having a stronger effect on survival than the
other loci. However, because this combined A/B
group included single allelic mismatches for A or B, as
well as mismatches for both A and B, the observed
effect may have been magniﬁed by these multiple
mismatches. Both Petersdorf et al. and Flomenberg et
al. found trends indicating that survival worsened with
increasing numbers of allelic mismatches. Another
concern is the generalizability of the Japanese study to
other races and ethnicities. The distribution of alleles
in the US and Japanese populations was quite differ-
ent, with little overlap in the alleles and mismatches
represented in the 2 populations. In addition, the
frequencies of GVHD reported in the matched cases
in the Japanese study were notably lower than those
reported by the Seattle group [7]. There may be other
immunologic factors that vary among ethnic or racial
groups and inﬂuence the relationship between HLA
matching and transplantation outcomes.
Only Flomenberg et al. [6] investigated the asso-
ciations between allele-level and serologic-level mis-
matches with survival. They found that only serologic-
level mismatches at HLA-A, -B, -C, and -DRB1 had a
separate statistically signiﬁcant effect on survival (P 
.01), although trends (.01  P  .05) were noted for
an effect of allele mismatches at HLA-A and -DR on
survival. To further assess the effect of allele-level
matching, they pooled allele-level mismatches across
loci to improve sample size among patients with do-
nors who were matched at the antigen level for
HLA-A, -B, and -DRB1 (often called “6-antigen
matched”). A single allele level mismatch at HLA-A,
-B, -C or -DRB1 was associated with an 8-12% re-
duction in survival at 5 years.
What Does the NMDP Suggest as Optimal Match
Criteria?
The reports listed previously suggest that it is
advantageous to match at the allele level for HLA-A,
-B, -C, and -DRB1. Thus, when possible, donors who
are allele level–matched at these 4 HLA loci are rec-
ommended. This does not imply that availability of
only HLA partially matched donors is a contraindica-
tion to transplantation.
Table 1. HLA Locus: Effect of Mismatching on Survival
Study A B C DRB1
JMDP Decrease* Decrease No effect No effect (merged
DR  DQ)
FHCRC Decrease (merged class I) Decrease (merged
DR  DQ)
NMDP Decrease Decrease Decrease Decrease
JMDP indicates Japanese Marrow Donor Program; FHCRC, Fred
Hutchinson Cancer Research Center.
*Decrease in survival caused by an HLA locus mismatch; “no effect”
means no effect of a mismatch.
Table 2. Similarities and Differences in Design of the 3 Studies
Variable JMDP-Morishima FHCRC-Petersdorf NMDP-Flomenberg
Source of transplants Multicenter Single center Multicenter
Stem cell source Marrow Marrow Marrow
Patient diseases AML, ALL, CML, MDS, SAA,
others
CML CML, AML, ALL, MDS, SAA,
others
Median patient age, y (range) 23 (0-51) 36 (1-55) (2001 study) 30 (0-66)
Patient race Japanese Predominantly white from the
United States
Predominantly white from the
United States
No. of pairs evaluated 1298 300 (1998), 548 (2001) 1874
HLA loci characterized (groups
of loci that were collapsed for
analysis are shown in
brackets)
[A, B] [C] [DRB1, DQB1] [A, B, C] [DRB1, DQB1, DPB1] [A] [B] [C] [DRB1] [DQA1,
DQB1] [DPA1 DPB1]
Match criteria for patients
entered into study
Serologic A-, B-, DR-matched
only
Serologic matching at A, B, and
DR with Dw or DRB1 allele
matching; mismatching
allowed within guidelines
described in 1998 study
Matching at serologic A and B
and serologic or allele level at
DRB1; 5 of 6 minimum
match
Level of match investigated Allele level Allele level Allele level and serologic level
for A, B, C, and DRB1; any
level for DQ and DP
AML indicates acute myeloid leukemia; ALL, acute lymphocytic leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome;
SAA, severe aplastic anemia.
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Other non-HLA factors are often considered
when donors are selected, including cytomegalovirus
(CMV)–negative serology (for patients with CMV-
negative serology), male sex, younger age, ABO com-
patibility, larger body weight, and matched race. The
NMDP found that, besides donor HLA matching,
younger donor age was associated with better survival.
There was no signiﬁcant association of donor CMV
serology for CMV-negative patients, sex, parity, race,
or ABO matching and survival. Female donors with
multiple pregnancies were associated with a higher
risk of chronic GVHD, but there was no effect on
survival [8].
For patients who have multiple highly matched
suitable donors, there might be additional beneﬁt
frommatching HLA-DQB1, -DPB1, and -DRB3/4/5.
However, the association between HLA-DQ and -DP
mismatching and mortality remains unproven, and the
association of HLA-DRB3/4/5 mismatching and sur-
vival has not been studied. There are no convincing
data to show that deliberate HLA mismatching may
be beneﬁcial to achieve graft-versus-leukemia effects.
How and at What Resolution Should My Patient
Be HLA-Typed?
DNA-based testing methods should be used to
identify the patient’s HLA alleles at the time a search
is initiated. Some loci should be characterized because
they are important in matching; others assist in de-
signing an efﬁcient search strategy for the patient
(Table 3).
HLA typing of members of the patient’s immedi-
ate family (candidate donor siblings, parents, and chil-
dren) is necessary to identify a potential related donor,
to conﬁrm patient HLA assignments, and to deﬁne
patient haplotypes—that is, to deﬁne which alleles are
localized on each chromosome. Haplotype identiﬁca-
tion is important in developing search strategies be-
cause this information is used to predict the probabil-
ity of ﬁnding allele-matched donors. Family typing is
particularly helpful if the patient seems to be homozy-
gous at a locus or carries rare alleles.
It is important to initially type the patient as well
as possible, because this provides an optimal founda-
tion for the entire search process. Although allele-
level typing may require more time than lower-reso-
lution testing, it ultimately speeds better donor
selection, allows evaluation of the difﬁculty of the
search, enables better matching leading to fewer
transplantation complications, and, in case a complete
match is not available, allows the process to proceed
more rapidly to the search for a partially matched
donor.
How Do I Search for the Best Donor?
A local or NMDP histocompatibility expert
should be contacted for assistance in generating a
search strategy and in selecting potential donors from
the NMDP search report for higher-resolution HLA
testing. This complex subject cannot be covered in
detail here. In general, the patient’s HLA assignments
(including haplotype assignments) are used to predict
the probability of ﬁnding a matched donor. Knowl-
edge of types that are difﬁcult to accurately assign can
be used to identify patient antigens that may be in-
correctly typed in the donor pool. Once a search
report is generated, knowledge of the associations
between HLA alleles (eg, B-C allele associations), fre-
quencies of HLA alleles in each racial or ethnic group,
and correlations among the HLA types obtained by
different testing methods are used to predict which
donors and how many donors must be HLA-typed at
higher resolution.
The optimal number of potential donors to select
from the search report should be customized for each
patient, because many factors inﬂuence the likelihood
of ﬁnding a donor. Factors to be considered include
the patient’s alleles, haplotypes, and clinical urgency.
For patients with highly conserved haplotypes, further
typing of a small number (3-5) of donors is usually
sufﬁcient. More than 1 donor should be selected be-
cause donors may be unavailable, mistyped, or not
matched at an allele level. For patients with rare alleles
and haplotypes, 10 donors may be required to ﬁnd
the best match. In a clinically urgent search, multiple
donors should be simultaneously evaluated.
Table 3. Typing of Patient HLA Loci
HLA Locus Search Strategy Matching
A Yes Recommended
B Yes Recommended
C Yes Recommended
DRA No No
DRB1 Yes Recommended
DRB3, DRB4, DRB5 Yes (DRB1 association)* Unknown†
DQA1 No No
DQB1 Yes (DRB1 association)* Uncertain†
DPA1 No No
DPB1 No Uncertain
*Certain alleles at one locus are preferentially associated with some
but not other alleles at a second locus. Knowledge of the pa-
tient’s HLA-DRB3/4/5 or DQB1 assignment can predict which
donors also typed for these loci are most likely to carry speciﬁc
DRB1 alleles. For example, a donor might be typed as
DRB1*1301 or DRB1*1302. Both of these alleles are common.
Each allele has a speciﬁc association with DRB3: DRB*1301 is
usually associated with DRB3*0101 or DRB3*0202 and rarely
with DRB3*0301. In contrast, DRB*1302 is usually associated
with DRB3*0301 and rarely with DRB3*0101 or DRB3*0202.
†Unknown indicates that the effect of matching has not been
evaluated; uncertain indicates that studies disagree as to the
importance of these loci in matching.
C. Katovich Hurley et al.
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How Should Potentially Matched Donors Be
HLA-Typed?
Donors selected from the NMDP search report as
potential matches should have higher-resolution test-
ing to select the best HLA match. DNA-based testing
methods should be used to identify the donor’s HLA
alleles (Table 4). Some loci should be characterized
because they are key to matching; others (labeled
unknown or uncertain) should be typed to allow se-
lection of the best match once other donor character-
istics have been taken into account. An HLA expert
might recommend a strategy that initially targets se-
lected loci for higher-resolution typing to reduce the
typing cost; however, this approach should be consid-
erate of the recipient’s medical condition so as not to
unduly delay an urgent transplantation.
Does the Race or Ethnicity of the Donor Need to
Be the Same as the Race or Ethnicity of the
Recipient?
HLA alleles and haplotypes are distributed at dif-
ferent frequencies in different racial or ethnic groups.
When searching for a donor, for some alleles, an
allele-level match is more likely to be found among
persons of a particular ethnicity. For alleles and hap-
lotypes found frequently in several races or ethnicities,
donors from these populations should be evaluated.
Once allele matches are identiﬁed, the race or ethnic-
ity of the matched donor should have no effect on the
outcome of the transplantation. When donor/recipi-
ent pairs serologically matched at HLA-A, -B, and
-DRB1 by using DNA-based typing were compared,
there was no advantage to being matched by race [8].
It should be recognized that the number of racially
mismatched donor/recipient pairs in this study was
small, and further studies are needed to conﬁrm these
data.
How Long Do I Search for Donors?
For patients with common haplotypes, a suitably
matched donor can usually be identiﬁed within 4 to 6
weeks. It may take much longer to identify a donor for
less common HLA types. For patients with uncom-
mon types, we recommend that help be requested
from a local or NMDP HLA consultant to ﬁnd the
best match.
If an acceptably matched donor cannot be identiﬁed
within the current NMDP registry, it is very unlikely
that newly recruited donors will match the patient in a
useful time frame. The NMDP donor ﬁle contains 5
million donors (approximately 70% typed for HLA-A,
-B, and -DR), and each NMDP search also evaluates an
additional 3.5 million donors listed in Bone Marrow
DonorsWorldwide, so patients who do not ﬁnd a match
in this pool must have infrequent haplotypes. The
NMDP adds 20 000 to 25 000 donors to the ﬁle
monthly. The likelihood that a recipient’s type will be
represented in those new recruits when it did not appear
in the initial ﬁle of 5 million is exceedingly low. There-
fore, it is recommended that alternative treatment op-
tions be re-evaluated for those patients and a decision
made as to whether to reduce the matching require-
ments or select another therapy (eg, unrelated cord
blood transplantation, a partially matched related donor
transplantation, or nontransplant therapy).
How Do I Select the Best Partially Matched
Unrelated Donor?
If there are no donors who are HLA-A, -B, -C,
and -DRB1 matched at the allele level, NMDP data
suggest that a single allele–level mismatch (eg, A*0201
donor and A*0205 recipient) is preferable to an anti-
gen-level mismatch (eg, A*0201 donor and A*1101
recipient). For patients with donors who are matched
at the antigen level (ie, a 6-antigen match), Flomen-
berg et al. [6] reported that a single allele–level mis-
match is associated with an 8% to 12% reduction in
survival at 5 years. This reduction in survival may be
acceptable given the survival rates for alternative
treatments.
On the basis of the NMDP data, an allele-level
mismatch is preferable to an antigen-level mismatch,
but there are as yet no data to distinguish the survival
effect of a single-antigen mismatch from that of 2
allele–level mismatches. Data from the Fred Hutchin-
son Cancer Research Center and NMDP studies sug-
gest that risks accompanying multiple mismatches
may be cumulative or even synergistic. If an antigen-
mismatched donor is to be used, any antigen mis-
match can be selected unless the patient is sensitized
to speciﬁc HLA antigens, as indicated by a positive
crossmatch test [9,10]. In a further analysis of NMDP
data, HLA mismatching within a serologic cross-re-
active group was not associated with a survival beneﬁt
Table 4. Typing of Potential Donor HLA Loci
HLA Locus Matching
Resolution
of Testing
A Recommended Allele level
B Recommended Allele level
C Recommended Allele level
DRA No
DRB1 Recommended Allele level
DRB3, DRB4, DRB5 Unknown*
DQA1 No
DQB1 Uncertain*
DPA1 No
DPB1 Uncertain
*Unknown indicates that the effect of matching has not been eval-
uated; uncertain indicates that studies disagree as to the impor-
tance of these loci in matching.
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in comparison to mismatches outside a cross-reactive
group. An abstract on this study by Wade et al. [11]
has been presented, and a manuscript has been ac-
cepted for publication [12].
Beyond these general guidelines, there are not yet
convincing data to rank the relative importance for
matching for a particular HLA locus (HLA-A, -B, -C,
or -DRB1) or for predicting permissible mismatches.
It is important to emphasize that within a particular
level of mismatch (ie, allele level or antigen level),
HLA-DRB1 matching is not more or less important
than matching for the HLA-A, -B, and -C loci.
More complex search strategies are required to
identify donors with speciﬁc mismatches for patients
who do not have matched donors. These strategies are
needed to limit the number of allele mismatches at
other loci. For these searches, we recommend that
help be requested from a local or NMDP HLA con-
sultant to ﬁnd the best mismatch.
Lack of a well-matched donor (HLA matched or a
single HLA-A, -B, -C, or -DRB1 mismatch) is not a
contraindication to transplantation. In this situation,
the physician should consider the success rate associ-
ated with the use of a mismatched donor versus the
use of other available treatment alternatives (using
HLA-mismatched related donors, unrelated umbilical
cord blood donors, and nontransplant therapies). In
summary, HLA matching at HLA-A, -B, -C, and
-DRB1 is best, and allele-level mismatching is pre-
ferred to antigen mismatching. More speciﬁc details
regarding matching remain controversial.
When Should I Launch an International Search for
a Donor?
Every NMDP search will include a general search
of Bone Marrow Donors Worldwide as well as an
automatic detailed search of certain international reg-
istries. Using the Bone Marrow Donors Worldwide
report as a guide, searches of other registries may be
initiated on ﬁling a speciﬁc request to NMDP. Be-
cause HLA alleles and haplotypes are distributed at
different frequencies in different racial or ethnic
groups, the usefulness of international searches will
depend on the patient’s alleles and haplotypes.
How Should the Clinical Status of My Patient
Influence the Selection of the Donor?
The clinical status of the patient will inﬂuence the
length of time it is feasible to search for a donor and
the degree of mismatch that is considered acceptable.
Patients with a relatively stable disease, such as newly
diagnosed chronic myelogenous leukemia in a stable
phase or low-risk myelodysplasia, are less likely to
deteriorate quickly. A search time of 4 months to
identify a donor contributes a small clinical risk. In
contrast, patients with acute leukemia may have only a
brief remission time in which transplantation is feasi-
ble. A prolonged search time exposes patients to ad-
ditional toxic chemotherapy, an increased risk of in-
fection, and risk of relapse. In these patients, a short
search and ongoing consideration of alternatives (au-
tologous transplantation, cord blood transplantation,
investigational therapy, and so on) is preferred.
The risk from underlying disease and the avail-
ability of therapeutic alternatives also inﬂuence the
degree of mismatch considered acceptable by the phy-
sician and patient. Besides considering differences in
life expectancy, the quality of life associated with
transplantation from the best available unrelated do-
nor should be compared with the quality of life asso-
ciated with alternative therapies.
Does the Reduced Intensity of the Conditioning
Protocol Influence the Level of HLA Match That I
Select?
There are currently no data to indicate that
greater degrees of mismatch are less tolerable in the
setting of a reduced-intensity transplantation regimen.
The risk of using a mismatched donor must be
weighed against the other therapeutic options avail-
able to the patient.
What HLA Matching Is Required for Stem Cell
Sources Other Than Marrow?
The data summarized previously involve bone
marrow as a stem cell source. At this time, there are no
large studies of alternative stem cell sources that have
used allele-level HLA typing.
One alternative stem cell source for cases without
a suitable donor is the use of umbilical cord blood.
Initial reports of umbilical cord blood transplantations
have shown that cell dose is the most important de-
terminant of survival. In addition, HLA matching
does inﬂuence outcome, with better survival in better-
matched recipients [13,14]. The precise inﬂuence of
HLA mismatching on cord blood transplantation re-
sults remains to be deﬁned.
The data currently available regarding the role of
HLA mismatch in transplantation outcome are gener-
ated from series using bonemarrow as a stem cell source.
Additional analyses of transplantations using peripheral
blood stem cells as a stem cell source are needed to
determine whether the same principles apply.
If the Patient Has a Mismatched Donor, Should I
Use T-Cell Depletion?
T-cell depletion (TCD) reduces the incidence and
severity of acute GVHD, and increasing donor mis-
match increases risk of GVHD. Despite this, analysis
of the NMDP dataset does not indicate a survival
advantage for TCD, whether a graft is matched or
mismatched. A prospective randomized trial of TCD
C. Katovich Hurley et al.
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did not show improved survival associated with the use
of TCD in either matched or mismatched unrelated
donor transplants [15].
Should We Be Considering Other Loci in Addition
to HLA for Donor Selection?
At this point in time, there are insufﬁcient data to
advocate matching of loci other than HLA.
Should Targets of Natural Killer Cell
Alloreactivity Be Considered?
There are currently no data to indicate that unre-
lated donors with mismatches at HLA class I should be
preferred in any clinical circumstance. A recent report
indicated a strong antileukemic effect and survival ad-
vantage with haploidentical related donor transplants
with particular HLA class I mismatches that generate
donor killer cell reactivity directed toward patient tissues
[16]. This association was observed only for recipients
with acute myeloid leukemia. Application of a similar
mismatching algorithm to 2 small, unrelated donor
transplant series has generated conﬂicting data [17,18].
In one series by Giebel et al. [17], in which pretransplan-
tation antithymocyte globulin was used to achieve TCD
in vivo and patients received relatively high cell doses,
HLA-B or -Cmismatching for a killer cell immunoglob-
ulin-like receptors (KIR) binding epitope was associated
with better survival. In contrast, the Davies et al. study
[18] showed no advantage for KIR ligand incompatibility
(ie, deliberate but selected mismatches of HLA-B and
-C) for survival. The negative result of the study by
Davies et al. may reﬂect the fact that only a minority of
cases in this study received T cell–depleted stem cells,
and, even in the depleted cases, a relatively high number
of T cells were included in the graft. A study to assess the
role of KIR alloreactivity in the large NMDP unrelated
donor transplant population is in progress.
Where Can I Find Additional Information?
NMDP web sites include http://www.marrow.org/
and http://www.nmdpresearch.org/.
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